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Abstract
Background: Complete resection of pelvic bone tumors, especially recurrent and metastatic ones, is often
impossible to achieve using conventional surgery. This study aimed to assess the benefits and adverse effects of
computed tomography (CT)-guided radioiodine (125I) brachytherapy for inoperable recurrent and metastatic bone
tumors of the pelvis.
Methods: This was a retrospective study of 22 patients with confirmed pelvic bone tumors (10 females and 12
males; 15–84 years; 21 with primary pelvic tumor and one with pelvic metastasis). CT-guided 125I brachytherapy was
performed using 9–21 125I seeds (radioactivity of 0.5–0.7 mCi). Seed implantation was validated by postoperative CT
scanning. Complications, pain, survival, and CT-estimated tumor size were carried out to evaluate the therapeutic
benefits.
Results: Postoperative CT scans revealed satisfactory 125I seed implantation, and the radiation dose delivered to
90% of the target area (D90) was higher than the prescription dose (PD). No obvious complications were observed.
Pain was reported by 19 of 22 patients, but 17 reported pain relief after implantation. Follow-up ranged 8–27
(median, 19) months. Tumor size was reduced in 11 patients within 1 month after surgery, nine patients showed no
change, and tumor size increased in two patients. Finally, 1- and 2-year survival was 81.8 and 45.5%, respectively;
1- and 2-year local tumor control rates were 59.1 and 36.4%, respectively.
Conclusions: 125I seed implantation significantly reduced bone tumor size and relieved pain, with a low
complication rate. These findings suggest that 125I brachytherapy treatment could be a useful palliative approach
for pelvic bone tumor treatment.
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Background
Malignant bone tumors severely affect patient quality of
life and are associated with low survival, high disability,
recurrence, and mortality. In the 1970s, hemi-pelvic re-
section was the routine approach for patients with ma-
lignant pelvic bone tumor but only achieved a 15% 5-
year survival rate. Survival was increased to 50–80% in
recent years by applying comprehensive and multidiscip-
linary treatment strategies such as surgery combined
with chemo-radiotherapy [1]. However, despite that sur-
gery is considered as the only curative approach for bone
tumors, complete resection of pelvic tumors with con-
ventional surgery is hard to achieve due to the invasive-
ness of malignant bone tumors and complicated
anatomic structure of the pelvis [2, 3]. The local recur-
rence rate of pelvic tumors is as high as 39.3% after
conventional therapy [4, 5], and most patients are not
fit enough to undergo a second surgery. In addition,
the narrow therapeutic window of conventional chemo-
therapy drugs makes it difficult to increase the concen-
trations of drugs within the tumor tissues to improve
local tumor control [6].
Brachytherapy, also known as internal radiotherapy,
involves a micro-radiation source placed inside or next
to a tumor. The maximum effective treatment is
achieved by continuous irradiation with low-energy X-
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rays. A key feature of brachytherapy is localized irradi-
ation, which significantly reduces the probability of un-
necessary damage to surrounding healthy tissues [7], as
observed in the treatment of various types of cancer [8].
There is no need to ensure adequate exposure of the tar-
get area or perform radical resection of the tumor tissue
with conventional surgery; therefore, brachytherapy can
significantly reduce surgical trauma [9]. 125I is a syn-
thetic low-energy radiation source with short radiation
range and a half-life of 60.1 days. It has several advan-
tages such as long half-life, safety, reliability, and low
pollution. 125I may cause anti-tumor effects by various
mechanisms: (1) induction of tumor cell apoptosis, (2)
promotion of tumor cell cycle arrest, (3) interference
with tumor cell signal transduction, and (4) prevention
of tumor tissue angiogenesis [10]. Grossman et al. first
reported the success of 125I brachytherapy in the treat-
ment of prostate cancer, with 5- and 9-year survival rates
of 83 and 52%, respectively [11]. Although 125I brachy-
therapy is used as an effective treatment approach for
prostate, digestive tract, lung, liver, and pancreatic can-
cers, it remains controversial due to local adverse effects
such as skin ulceration and skin sinus formation, bladder
irritation syndrome, proctitis, rectum ulceration, and
prostate rectum fistulae. In addition, peripheral pulmon-
ary emboli can occur if radiation seeds enter the sys-
temic circulation.
Effective brachytherapy for pelvic tumors requires a
high level of precision regarding the position and
dose of radiation seeds in order to reduce possible
adverse effects. Indeed, the complicated anatomical
structure, abundant neurovascular networks, and the
specific pathological type of pelvic tumor have to be
taken into consideration. Probably because of the dif-
ficulties associated with pelvic operations, reports re-
garding 125I brachytherapy for the treatment of pelvic
tumors are scarce.
This retrospective study aimed to assess the clinical
data of 22 patients who underwent 125I brachytherapy
between September 2009 and April 2011 for the pallia-
tive treatment of inoperable bone tumors in the pelvis.
The computed tomography (CT)-guided 125I brachyther-




This was a retrospective study of all patients with pelvic
bone tumor treated with 125I brachytherapy by the Bone
Tumor Group, Orthopedic Surgery, Shanghai Tenth
People’s Hospital. Twenty-two patients (10 females, 12
males) were assessed, including six patients with chor-
doma; three with osteosarcoma and giant cell tumor;
two with chondrosarcoma, fibrosarcoma, and melanoma;
and one with leiomyosarcoma, large B cell lymphoma,
intermuscular hemangioma, and neurilemmoma. Ex-
cept for the patient with large B cell lymphoma, the
other 21 cases had primary bone and soft tissue malig-
nant tumors after the first conventional surgery, includ-
ing the patient with melanoma with local recurrence
and adjacent pelvic skeleton erosions. All diagnoses
were confirmed by experienced pathologists. Patients
were 15–84 years of age (median, 43 years). There was
no indication of surgery for the pelvic tumors. Nineteen
patients complained of various degrees of pain in the
pelvis or lower extremities.
125I brachytherapy was carried out with the intent to
narrow the resection scope of conventional surgery, re-
duce recurrence rate, improve the completeness of
tumor resection, and preserve organ function. Inclusion
criteria were as follows: (1) the tumor proliferated and
locally infiltrated the surrounding organs or tissues; (2)
the tumor was not easily resectable, due to large major
axis length (>6 cm), extension to adjacent vasculature
and nerves, and/or no clear margin; (3) isolated recur-
rent or metastatic bone tumor; (4) need to treat localized
residual pelvic cancer after conventional surgery or ex-
ternal radiation therapy; (5) the patient declined con-
ventional surgery or was unfit for conventional surgery;
(6) no history of radiotherapy to the pelvis; and (7) the
patient accepted brachytherapy using 125I seeds. The
exclusion criteria were (1) active tumor bleeding, ne-
crosis, or ulceration; (2) cancer infiltration into a large
area or involving a large blood vessel; (3) non-
suitability of the patient for radiotherapy, or contraindi-
cation to anesthesia; or (4) closeness of large vessels to
seed implantation site.
This study was approved by the ethics committee of
Shanghai Tenth People’s Hospital. The need for individ-
ual consent was waived by the committee because of the
retrospective nature of the study.
Instrument and reagents
An 18-gauge, 200-mm long puncture needle (Dr. J,
Japan) was used for the delivery of the 125I seeds, which
were purchased from the China Institute of Atomic En-
ergy (Beijing, China). The 125I seeds were cylindrical
(0.8 mm × 0.45 mm) with titanium capsules. The average
energy was 27–35 keV, and the radioactivity ranged 0.5–
0.7 mCi, with a half-life of about 60 days. Tissue pene-
tration was about 17 mm. The initial dosing was 7 cGy/
h. The TPS-200 analysis system was purchased from
Hokai Medical Equipment Co. Ltd. (Zhuhai, China).
Preoperative preparation
Each patient underwent thin-layer CT (Brilliance 64,
Philips, Best, The Netherlands) 1 week before operation.
The planning target volume (PTV) was designed to be a
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bit larger than the gross tumor volume (GTV), with 1.5-
cm outward extension. A three-dimensional planning
system (TPS) was used to design the optimal route
around functional sensitive regions or organs. Calcula-
tions were undertaken for the required numbers of seeds
and radioactivity coverage using the Hailar formula, de-
termining the target region of the tumor, implantation
site of seeds, and dosage distribution. The Hailar for-
mula used in the current study was Hailar coefficient
(Da) = (tumor length + width + height)/3; total activity of
the seeds = Da × 5; number of implanted seeds = total ac-
tivity/individual seed activity. The final number of seeds
ranged from 9 to 21, with a median of 4.5.
Implantation
The puncture site was determined under CT guidance.
Then, the puncture needle was positioned to the prede-
termined site and depth after routine disinfection and
anesthesia. The radioactive seeds were implanted
through the needle and their position was confirmed
with a CT scan. The seeds were implanted with a high
density at the peripheral site of the target region and
relatively sparsely at the center to achieve homogeneous
radioactivity distribution. The implanted seeds were dis-
tributed in a fan-shape, with approximately 1 cm be-
tween each seed. All operations were performed by two
orthopedic surgeons (Drs. Xiaojun MA and Chongren
Wang), and intraoperative localization was carried out
with CT-scan navigation. Radioactivity protections were
used during the operation.
Postoperative evaluation
The TPS system was used for postoperative (1 month)
evaluation, and a CT scan was performed for each pa-
tient. The therapeutic effect was assessed using pain se-
verity, tumor size, survival, and complications. Pain
severity was graded according to the WHO standards
[12]: grade 0, no pain; grade I, tolerable pain, no obvious
effect on sleep or regular daily life; grade II, obvious in-
tolerable pain, seriously interference with sleep, analge-
sics required; grade III, severe unbearable pain with
disrupted sleep, associated with passive positional
changes of nerves or functional autonomic nerve dis-
order. Pain relief outcome was classified as significantly
effective (pain severity decreased by two grades or
complete pain relief ), effective (pain severity decreased
by one grade), or invalid (no obvious pain relief or more
severe pain) [13]. The KPS and VAS systems were used
to assess patient symptoms, quality of life, pain, and dis-
ability, before and after treatment. Patients were reexa-
mined by CT 2 months after surgery; the same
radiologist assessed each patient before and after oper-
ation. Tumor remission was defined according to the
following standards [14–16]: obvious remission (OR),
tumor volume (0.5 × long axis × short axis × short axis)
decreased by more than 50%; partial remission (PR), vol-
ume decreased by 25–50%; slight remission (SR), volume
decreased by less than 25%; no remission (NR), no de-
crease or increased volume.
Statistical analysis
Continuous variables were presented as median and
interquartile ranges (IQRs) and were analyzed using the
paired t test. P ≤ 0.05 was considered statistically signifi-
cant. Statistical analyses were carried out using SPSS
17.0 (IBM, Armonk, NY, USA).
Results
Short-term evaluation after radioactive seed implantation
Postoperative CT and TPS evaluation revealed satisfac-
tory 125I seed implantation, with a median radiation dose
of 45 cGy (IQR 27.5–85.0 cGy) delivered to 90% of the
target area (D90) and surpassing the prescription dose
(PD) (D90 > PD). Dose inhomogeneity was no more than
20% PD. In the present study, 19 out of 22 patients
showed decreased postoperative tumor volumes (Fig. 1,
Table 1), and OR, PR, and SR were achieved in two, 14,
and three patients, respectively.
Fig. 1 125I seed distribution and tumor size after brachytherapy. A1,
A2, and A3 were obtained before brachytherapy; B1, B2, and B3
were recorded 2 months after brachytherapy. Seeds were evenly
distributed within tumors, which were reduced in size after treatment.
Obvious remission was observed in B1 and B3 (A1 diameters, 12.5 and
3.7 cm; B1 diameters, 7.3 and 2.1 cm; A3 diameters, 14.7 and 5.2 cm; B3
diameters, 5.6 and 3.3 cm). Partial remission was observed in B2 (A2
diameters, 11.2 and 6.7 cm; B2 diameters, 9.8 and 5.9 cm)
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Table 1 Patient characteristics and tumor size pre- and post-125I seed implantation in the 22 patients
Pre-implantation tumor characteristics Post-implantation (1 month) tumor characteristics
Gender Age Pathological type Dose (cGy) Major axis (cm) Minor axis (cm) Volume (cm3) Major axis (cm) Minor axis (cm) Volume (cm3)
M 34 Chordoma 80 16.7 10.2 839.2 14.5 9.1 604.65
M 58 Chordoma 30 10.1 7.9 314.7 6.6 5.2 88
M 58 Chordoma 100 22 14.4 2288 22 14.6 2346.3*
M 84 Chordoma 100 19.1 12.3 1441.7 14.8 11.8 1025.64
F 43 Chordoma 50 8 3.7 54.4 7 3.3 39.2
F 47 Chordoma 30 13.3 6.3 267.9 12.1 4.9 148.1
M 20 GCT 20 8.9 5.6 142 8 5.1 111
M 30 GCT 100 20 11.6 1350 18 9.2 768.6
F 64 GCT 60 6 4.7 67.5 5.8 4 46.4
M 75 Osteosarcoma 70 9.8 3.9 76.3 9.7 3.5 60.5
F 15 Osteosarcoma 80 18 9.6 828 14.7 8.9 582.12
F 20 Osteosarcoma 60 15.6 9.4 683.3 9.7 8.1 494.7
M 39 Chondrosarcoma 30 10.3 6.9 248 9.1 6.1 168
M 46 Chondrosarcoma 20 9.3 6.5 195.3 6.6 5.7 107.1
M 54 Fibrosarcoma 100 20.9 12.7 1681.6 19.7 12 1427.3
F 60 Fibrosarcoma 40 14.4 8.1 474.2 15.3 8.3 523.3*
F 24 Malignant melanoma 30 10.7 7.4 293.9 10 6.5 209
F 50 Malignant melanoma 30 10 7.7 368 9.5 7.5 267
M 39 B-DLCL 20 8.5 5.8 142.8 3.8 2.7 13.4
F 44 Hemangioma 10 7.4 4.6 79.5 6.5 3.9 50.7
M 61 Leiomyosarcoma 100 14.7 12.1 1070 15 13.1 1300.7*
F 16 Mesenchymal neoplasm 10 7.8 3.6 49.2 7.2 3.1 34
















Regional pain was significantly alleviated in all patients
after surgery. The VAS scores were significantly de-
creased at 1 month after implantation compared with
the pre-implantation scores (P < 0.05; Table 2), but there
was no intergroup difference at 1, 3, or 6 months after
implantation (all P > 0.05). Nineteen patients reported
pain after surgery, including one patient with grade I
pain, eight with grade II, and 10 with grade III. One
month after surgery, eight patients experienced signifi-
cant pain relief, and nine reported effective pain relief,
indicating an overall pain relief rate of 89.5%. Three
months after implantation, seven patients had significant
pain relief, and eight reported effective pain relief, for a
pain relief rate of 78.9%. At 6 months after the implant-
ation, four patients experienced significant pain relief,
and six had effective pain relief, indicating an overall
pain relief rate of 52.6%. Two patients reported complete
pain relief until death. The KPS scores were significantly
increased at 1 month after implantation compared with
the pre-implantation scores (P < 0.05; Table 2). Three
months after surgery, KPS scores for pain showed a fur-
ther relief compared with 1 month post-implantation
scores (P < 0.05), but the changes were not significant
(P > 0.05) 3 months after seed implantation.
Complications
No complication associated with seed implantation (such
as infection, active bleeding, nerve damage, fracture, and
bone radiation necrosis) was observed. One patient ex-
perienced defecation dysfunction due to tumor progres-
sion 4 months after implantation.
Long-term follow-up
Follow-up was 8–27 months, with a median of
19 months. The 1- and 2-year survival rates were 81.8
and 45.5%, respectively (Fig. 2). The main cause of death
was multi-organ failure. The 1- and 2-year local control
rates were 59.1 and 36.4%, respectively (Fig. 3).
Discussion
Pelvis bone tumors, either primary or metastatic, often
compress the adjacent soft tissues, vessels, and nerves,
causing local pain, lower extremity edema, dysfunction,
and paralysis. It is often impossible to achieve the radical
resection of bone tumors of the pelvis because of the
proximity of delicate organs and structures such as the
bladder, rectum, sciatic nerve, and blood vessels [17, 18].
Although it is not very clear whether 125I implantation is
effective against pelvis bone tumor, some reports have
shown the effectiveness of external beam radiotherapy
for asymptomatic or ambulatory patients with spinal
cord metastases [19]. Brachytherapy has also been
shown to be effective and safe in patients with spinal tu-
mors [20–22]. Because of similar considerations in terms
of delicate surrounding tissues and the risk of iatrogenic
injury, the therapeutic approaches to spine and pelvis tu-
mors share some features. Therefore, 125I implantation
could be an important treatment modality for the quality
of life of patients with pelvic bone tumors.
Radiation therapy is accepted as the first-line treat-
ment for most patients with metastatic spinal tumors
[23]. 125I brachytherapy was introduced for the treat-
ment of prostate cancer in 1965 [24, 25]. The application
of 125I brachytherapy in the treatment of spinal metasta-
ses has been reported with positive therapeutic efficacy
[26–29]. Therefore, radioactive seeds could be applied
for the treatment of pelvic bone tumor. The present
study suggested satisfactory therapeutic effects of 125I
brachytherapy for the palliative treatment of inoperable
recurrent and metastatic pelvic tumors. Accurate im-
plantation of radioactive seeds could be the key to
achieving good therapeutic outcomes. A recent study
using ablative radiation dose approach showed that
CT-guided interstitial brachytherapy for recurrent ano-
rectal cancer achieved durable tumor control, effective
palliation, improved long-term survival, and minimal
long-term morbidity [30]. Another study showed that
high-dose brachytherapy achieved high local control
rates and low toxicity in patients with pelvis tumors
that were not readily accessible to other therapies [31].
Taken together, these previous studies and the present
study suggest that brachytherapy could achieve high-
precision treatment of tumors of the pelvic area, with
minimal damage to other organs and tissues.
The low-energy radioactivity released from 125I seeds
in a single spot is negatively associated with the squared
distance to the position of the seeds; therefore, radio-
activity rapidly decreases as the distance increases. The
implanted seeds should be evenly distributed and
sparse distribution cannot guarantee an effective dos-
age. Moreover, a too dense distribution is a waste of
radioactive material and can cause adverse effects. CT
scanning parameters such as thickness, spacing interval,
and scanning direction were rigorously identical be-
tween the pre- and intra-implantation CT scans to fa-
cilitate seed implantation accuracy. Seed numbers and
positions were chosen strictly according to the pre-
operative design, with the puncture route carefully
Table 2 Preoperative and postoperative VAS and KPS scores
Evaluation KPS VAS
Pre-implantation 44.5 ± 7.2 7.2 ± 1.9
1 month post-implantation* 73.2 ± 7.0 4.7 ± 1.1
3 months post-implantation* 75.0 ± 6.6 3.8 ± 1.2
6 months post-implantation* 75.9 ± 7.2 3.6 ± 1.0
*All values given as mean ± SD, p < 0.05 compared with the preoperative scores
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selected to avoid injury to adjacent vessels or organs.
This could be associated with the low rate of
implantation-induced complications observed in the
present study. The puncture angle, depth, and position
of the needle tip were also adjusted under CT guidance
to ensure implantation safety and accuracy. Post-
implantation CT scanning was performed immediately
to assess seed distribution and determine possible com-
plications. CT scanning was also used during follow-up
to assess the therapeutic effects. The present study
showed that tumor size (Fig. 1, Table 1) and pain were
significantly reduced, which is supported by a previous
study [32]. Furthermore, it was reported that adverse
side effects of brachytherapy mainly involve local adja-
cent organs [33–36]. Therefore, CT scanning was per-
formed throughout the whole treatment procedure to
ensure implantation accuracy and effectively avoid
short- and long-term complications.
In the present study, 1- and 2-year survival rates of
81.8 and 45.5%, respectively, were observed, while the 1-
and 2-year local tumor control rates were 59.1 and
36.4%, respectively. These rates are greater than those
described for conventional radiotherapy, as reviewed by
Lutz et al. [37]. Indeed, external beam radiotherapy for
Fig. 3 Local tumor control rates after 125I brachytherapy
Fig. 2 Kaplan-Meier survival curve after 125I brachytherapy
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bone tumors has been shown to provide complete pain
palliation for 33% of patients, but with acute and late
toxicity rates of 10–37 and 1–11%, respectively [37]. In
addition, median survival was around 2–4 months [37].
The present study suggests that better outcomes could
be achieved with brachytherapy, as supported by previ-
ous studies. Indeed, percutaneous 125I seed implantation
has been proposed as an alternative or retreatment op-
tion for recurrent spinal primary tumors [38]. In
addition, this approach was recently described for the
treatment of malignant osseous tumors [39].
A few limitations of this study should be mentioned.
First, the sample size was small and from a single center,
which might affect both the accuracy of our findings and
their generalizability. In addition, subdividing the pa-
tients into primary and metastatic tumor subgroups was
not possible because of the small sample size. Finally, a
number of different types of tumors were included,
which could bias the results because of different radio-
sensitivity. Nevertheless, our results provide a basis for
the treatment of patients with malignant pelvic bone tu-
mors not treatable by conventional methods.
Conclusions
The results of the present study suggest that 125I brachy-
therapy could be considered a novel minimally invasive
palliative treatment for inoperable recurrent and meta-
static bone tumors of the pelvis. The procedure is likely
to be a useful approach with few adverse effects. How-
ever, further multicenter randomized studies with a lar-
ger sample size are needed to confirm these findings.
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